PL3577135T3 - Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 - Google Patents

Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5

Info

Publication number: PL3577135T3
Authority: PL; Poland
Prior art keywords: prevention; treatment; pharmaceutical composition; related diseases; diseases
Prior art date: 2017-01-31

Application number

PL18710159.7T

Other languages

English (en)

Inventor

Kenji SHINOMIYA

Koichiro YONEYAMA

Norihito Shibahara

Yoshinori Tsuboi

Taku FUKUZAWA

Kenta HARAYA

Zenjiro Sampei

Katrijn BOGMAN

Jean Eric CHAROIN

Original Assignee

Chugai Seiyaku Kabushiki Kaisha

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-31

Filing date

2018-01-31

Publication date

2023-12-04

2017-01-31 Priority claimed from SG10201700775YA external-priority patent/SG10201700775YA/en

2017-07-20 Priority claimed from SG10201705954VA external-priority patent/SG10201705954VA/en

2018-01-31 Application filed by Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche Ag filed Critical Chugai Seiyaku Kabushiki Kaisha

2023-12-04 Publication of PL3577135T3 publication Critical patent/PL3577135T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Dermatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)

PL18710159.7T 2017-01-31 2018-01-31 Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 PL3577135T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SG10201700775YA SG10201700775YA (en)	2017-01-31	2017-01-31	A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
SG10201705954VA SG10201705954VA (en)	2017-07-20	2017-07-20	A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PCT/JP2018/003193 WO2018143266A1 (en)	2017-01-31	2018-01-31	A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Publications (1)

Publication Number	Publication Date
PL3577135T3 true PL3577135T3 (pl)	2023-12-04

Family

ID=61617058

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18710159.7T PL3577135T3 (pl)	2017-01-31	2018-01-31	Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5

Country Status (19)

Country	Link
US (3)	US20190367599A1 (pl)
EP (2)	EP3577135B1 (pl)
JP (4)	JP6383122B2 (pl)
KR (4)	KR20230043247A (pl)
CN (1)	CN110167961A (pl)
AU (2)	AU2018215039B2 (pl)
BR (1)	BR112019015426A2 (pl)
CA (1)	CA3051389A1 (pl)
CR (2)	CR20190403A (pl)
ES (1)	ES2947735T3 (pl)
IL (2)	IL307593A (pl)
MX (2)	MX2019007749A (pl)
MY (1)	MY201148A (pl)
PH (1)	PH12019501706A1 (pl)
PL (1)	PL3577135T3 (pl)
SG (2)	SG11201801401UA (pl)
TW (3)	TWI828672B (pl)
UA (1)	UA129282C2 (pl)
WO (1)	WO2018143266A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN2014DN10515A (pl)	2006-03-31	2015-08-21	Chugai Pharmaceutical Co Ltd
MX336725B (es)	2007-09-26	2016-01-28	Chugai Pharmaceutical Co Ltd	Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh)	2008-04-11	2020-08-01	日商中外製藥股份有限公司	重複結合複數個抗原的抗體
KR102568454B1 (ko)	2010-11-30	2023-08-18	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
KR101838645B1 (ko)	2014-12-19	2018-03-14	추가이 세이야쿠 가부시키가이샤	항-c5 항체 및 그의 사용 방법
TWI656133B (zh)	2014-12-19	2019-04-11	日商中外製藥股份有限公司	抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
EP3463461A4 (en)	2016-05-27	2020-05-20	Alexion Pharmaceuticals, Inc.	Methods for treatment of refractory generalized myasthenia gravis
KR102667023B1 (ko)	2016-06-14	2024-05-21	리제너론 파아마슈티컬스, 인크.	항-c5 항체 및 이의 용도
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
MX2020004284A (es)	2017-10-26	2020-10-28	Alexion Pharma Inc	Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua).
CN120571008A (zh)	2017-12-13	2025-09-02	瑞泽恩制药公司	抗c5抗体组合及其用途
US12460012B2 (en)	2018-06-04	2025-11-04	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
AU2019370295A1 (en) *	2018-10-30	2021-06-03	Alexion Pharmaceuticals, Inc.	Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
EP4003408A1 (en) *	2019-07-31	2022-06-01	F. Hoffmann-La Roche AG	Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
WO2021019036A1 (en) *	2019-07-31	2021-02-04	F. Hoffmann-La Roche Ag	Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
JP7798763B2 (ja) *	2019-10-25	2026-01-14	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｃ５関連疾患の治療または予防のための投与レジメン
CA3196434A1 (en) *	2020-10-23	2022-04-28	Krista K. JOHNSON	Methods of treating patients having complement disorders using anti-c5 antibodies
JP2024060738A (ja)	2022-10-20	2024-05-07	セイコーエプソン株式会社	気体分離膜

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
WO1994029351A2 (en)	1993-06-16	1994-12-22	Celltech Limited	Antibodies
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE69937291T2 (de)	1998-04-02	2008-07-10	Genentech, Inc., South San Francisco	Antikörpervarianten und fragmente davon
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
KR101077001B1 (ko)	1999-01-15	2011-10-26	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US6534058B2 (en)	2000-10-10	2003-03-18	Tanox, Inc.	Anti-C5 monoclonal antibodies
ES2283594T5 (es)	2001-08-17	2016-03-15	Genentech, Inc.	Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
ITMI20021527A1 (it)	2002-07-11	2004-01-12	Consiglio Nazionale Ricerche	Anticorpi anti componente c5 del complemento e loro uso
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es)	2002-12-16	2010-10-27	Genentech, Inc.	Variantes de inmunoglobulina y sus utilizaciones.
US20070116710A1 (en)	2004-02-03	2007-05-24	Leonard Bell	Methods of treating hemolytic anemia
US20050169921A1 (en)	2004-02-03	2005-08-04	Leonard Bell	Method of treating hemolytic disease
CN1942483B (zh)	2004-04-13	2012-09-26	弗·哈夫曼-拉罗切有限公司	抗p型选凝素抗体
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
SI2359834T1 (sl)	2006-03-15	2017-02-28	Alexion Pharmaceuticals, Inc.	Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
TWI700293B (zh)	2008-04-11	2020-08-01	日商中外製藥股份有限公司	重複結合複數個抗原的抗體
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
HUE061548T2 (hu)	2008-11-10	2023-07-28	Alexion Pharma Inc	Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
EP2545079A2 (en)	2010-03-11	2013-01-16	Rinat Neuroscience Corporation	ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
TWI667257B (zh)	2010-03-30	2019-08-01	中外製藥股份有限公司	促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
CN114015692B (zh) *	2013-03-14	2024-12-31	阿尔尼拉姆医药品有限公司	补体组分C5 iRNA组合物及其使用方法
US20160051673A1 (en) *	2013-03-29	2016-02-25	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) *	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
KR101838645B1 (ko) *	2014-12-19	2018-03-14	추가이 세이야쿠 가부시키가이샤	항-c5 항체 및 그의 사용 방법
WO2016209956A1 (en) *	2015-06-26	2016-12-29	Alexion Pharmaceuticals, Inc.	A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
WO2017123636A1 (en)	2016-01-11	2017-07-20	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-c5 antibodies for treatment
EP3408291A1 (en)	2016-01-25	2018-12-05	Shire Human Genetic Therapies, Inc.	Anti-c5 antibodies with enhanced ph switch

2018
- 2018-01-31 PL PL18710159.7T patent/PL3577135T3/pl unknown
- 2018-01-31 CR CR20190403A patent/CR20190403A/es unknown
- 2018-01-31 TW TW108110617A patent/TWI828672B/zh active
- 2018-01-31 KR KR1020237009640A patent/KR20230043247A/ko not_active Ceased
- 2018-01-31 IL IL307593A patent/IL307593A/en unknown
- 2018-01-31 SG SG11201801401UA patent/SG11201801401UA/en unknown
- 2018-01-31 KR KR1020187009861A patent/KR101949891B1/ko active Active
- 2018-01-31 BR BR112019015426-4A patent/BR112019015426A2/pt unknown
- 2018-01-31 SG SG10201908697X patent/SG10201908697XA/en unknown
- 2018-01-31 EP EP18710159.7A patent/EP3577135B1/en active Active
- 2018-01-31 IL IL268327A patent/IL268327B2/en unknown
- 2018-01-31 MX MX2019007749A patent/MX2019007749A/es unknown
- 2018-01-31 EP EP23165354.4A patent/EP4223774A3/en active Pending
- 2018-01-31 JP JP2018014743A patent/JP6383122B2/ja active Active
- 2018-01-31 CA CA3051389A patent/CA3051389A1/en active Pending
- 2018-01-31 KR KR1020227005327A patent/KR102514175B1/ko active Active
- 2018-01-31 CR CR20220563A patent/CR20220563A/es unknown
- 2018-01-31 TW TW112148241A patent/TW202412841A/zh unknown
- 2018-01-31 TW TW107103450A patent/TWI658834B/zh active
- 2018-01-31 CN CN201880005975.XA patent/CN110167961A/zh active Pending
- 2018-01-31 KR KR1020197004219A patent/KR102365871B1/ko active Active
- 2018-01-31 AU AU2018215039A patent/AU2018215039B2/en active Active
- 2018-01-31 WO PCT/JP2018/003193 patent/WO2018143266A1/en not_active Ceased
- 2018-01-31 US US16/480,047 patent/US20190367599A1/en not_active Abandoned
- 2018-01-31 UA UAA201909498A patent/UA129282C2/uk unknown
- 2018-01-31 ES ES18710159T patent/ES2947735T3/es active Active
- 2018-01-31 MY MYPI2019004320A patent/MY201148A/en unknown
- 2018-06-22 JP JP2018118937A patent/JP7141865B2/ja active Active
2019
- 2019-06-26 MX MX2022012931A patent/MX2022012931A/es unknown
- 2019-07-24 PH PH12019501706A patent/PH12019501706A1/en unknown
2020
- 2020-07-14 US US16/928,129 patent/US20200407432A1/en not_active Abandoned
2022
- 2022-09-12 JP JP2022144425A patent/JP7581292B2/ja active Active
2023
- 2023-03-10 US US18/181,641 patent/US20230250162A1/en active Pending
2024
- 2024-08-23 AU AU2024216280A patent/AU2024216280A1/en not_active Abandoned
- 2024-10-30 JP JP2024190237A patent/JP2025016617A/ja active Pending

Also Published As

Publication number	Publication date
JP2018141025A (ja)	2018-09-13
KR20230043247A (ko)	2023-03-30
IL268327B1 (en)	2025-05-01
AU2018215039A1 (en)	2019-09-19
TW201922286A (zh)	2019-06-16
KR20180099625A (ko)	2018-09-05
JP7581292B2 (ja)	2024-11-12
US20230250162A1 (en)	2023-08-10
JP2018123125A (ja)	2018-08-09
US20200407432A1 (en)	2020-12-31
US20190367599A1 (en)	2019-12-05
TW201831201A (zh)	2018-09-01
TWI658834B (zh)	2019-05-11
RU2019126664A3 (pl)	2021-05-25
CA3051389A1 (en)	2018-08-09
IL268327A (en)	2019-09-26
TWI828672B (zh)	2024-01-11
IL268327B2 (en)	2025-09-01
EP4223774A2 (en)	2023-08-09
UA129282C2 (uk)	2025-03-12
EP4223774A3 (en)	2023-09-27
KR102514175B1 (ko)	2023-03-29
BR112019015426A2 (pt)	2020-05-26
EP3577135A1 (en)	2019-12-11
JP2025016617A (ja)	2025-02-04
JP6383122B2 (ja)	2018-08-29
PH12019501706A1 (en)	2020-03-16
KR102365871B1 (ko)	2022-02-21
IL307593A (en)	2023-12-01
ES2947735T3 (es)	2023-08-17
NZ756629A (en)	2025-09-26
KR20220027265A (ko)	2022-03-07
EP3577135B1 (en)	2023-04-19
CN110167961A (zh)	2019-08-23
AU2024216280A1 (en)	2024-09-12
MX2019007749A (es)	2019-09-09
JP7141865B2 (ja)	2022-09-26
KR20190104982A (ko)	2019-09-11
RU2019126664A (ru)	2021-03-02
AU2018215039B2 (en)	2024-06-13
CR20220563A (es)	2022-12-07
TW202412841A (zh)	2024-04-01
MY201148A (en)	2024-02-07
KR101949891B1 (ko)	2019-02-19
SG10201908697XA (en)	2019-10-30
SG11201801401UA (en)	2018-09-27
JP2022168209A (ja)	2022-11-04
CR20190403A (es)	2019-10-10
MX2022012931A (es)	2022-11-08
WO2018143266A1 (en)	2018-08-09

Publication	Publication Date	Title
PL3577135T3 (pl)	2023-12-04	Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
ZA202004025B (en)	2021-09-29	Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
ZA201908165B (en)	2023-07-26	Compounds for the prevention and treatment of diseases and the use thereof
IL256085B (en)	2021-02-28	A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
IL255509B (en)	2021-04-29	Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
SMT202400271T1 (it)	2024-07-09	Composizione farmaceutica per l’uso nel trattamento o nella prevenzione di una patologia correlata a c5
IL274578A (en)	2020-06-30	Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL254142B (en)	2022-05-01	Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL272097A (en)	2020-03-31	Compounds for the prevention and treatment of medical disorders and their uses
IL281585B (en)	2022-04-01	Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
IL272495A (en)	2020-03-31	Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL275525A (en)	2020-08-31	A pharmaceutical preparation for the treatment of cancer
HUE045532T2 (hu)	2020-01-28	Preventív és/vagy terápiás szer immunbetegségekre
IL280389A (en)	2021-03-01	Bile acid receptor modulators conjugated to G.1 protein and methods of using them
EP3338771A4 (en)	2019-05-08	PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF TRAMADOL-ETORICOXIB CHLORHYDRATE FOR THE TREATMENT OF PAIN
HUE047272T2 (hu)	2020-04-28	Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
SG11202103070VA (en)	2021-04-29	Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases
IL265976A (en)	2019-06-30	Use of a compound, pharmaceutical preparation and therapeutic method for the treatment or prevention of convulsions
IL259383A (en)	2018-07-31	A compound for use in the prevention and treatment of neurodegenerative diseases
PT3191112T (pt)	2019-06-27	Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
IL257689B (en)	2021-03-25	Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
PL3352777T3 (pl)	2022-02-07	Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona
GB201718838D0 (en)	2017-12-27	Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en)	2017-09-20	Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201817346D0 (en)	2018-12-12	Compounds and pharmaceutical compositions thereof for use in the treatment of diseases